News

GSK topped the list, thanks to its June 2021 deal with iTeos for an anti-TIGIT called EOS-448 that totaled more than $2 billion in potential value—over $600 million of which came in upfront cash.
The mechanism has proven challenging, with GSK and iTeos becoming the latest companies to terminate an anti-TIGIT asset. Last month, BeiGene announced it was terminating development of ociperlimab ...
TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...
However, the earlier flops shook TIGIT players, with GSK and iTeos assessing “how best to proceed with additional clinical development” of their rival asset after a phase 3 Roche flop in 2022.
GSK said that the EOS-448/Jemperli combination will start a large randomised trial next year, adding that it now has drug candidates addressing "all three known CD226 checkpoints – TIGIT, CD96 ...
iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche's rival ...
GlaxoSmithKline is paying iTeos Therapeutics $625 million up front to share in the development of an antibody that targets the TIGIT protein, a hot target in cancer immunotherapy R&D.
GlaxoSmithKline has agreed to buy an anti-TIGIT antibody for cancer immunotherapy from iTeos Therapeutics for $625 million upfront and up to $1.45 billion in milestone payments.
Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target. Results come amid broader doubts about the approach among some. Manage alerts for this article; ...
TIGITs took another tumble with GSK plc’s decision to end a development program and a collaboration with Iteos Therapeutics Inc. New top-line results from a phase II study in non-small-cell lung ...
May 13 (Reuters) - Britain's GSK (GSK.L), opens new tab and drug developer iTeos Therapeutics (ITOS.O), opens new tab said on Tuesday they have stopped developing an experimental lung cancer drug ...